Suppliers and packagers for generic pharmaceutical drug: DALBAVANCIN HYDROCHLORIDE

DALBAVANCIN HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Fresenius Kabi Usa	DALBAVANCIN HYDROCHLORIDE	dalbavancin hydrochloride	POWDER;INTRAVENOUS	217591	ANDA	Fresenius Kabi USA, LLC	65219-120-12	1 VIAL in 1 PACKAGE (65219-120-12) / 25 mL in 1 VIAL	2025-11-10
Kindos	DALBAVANCIN HYDROCHLORIDE	dalbavancin hydrochloride	POWDER;INTRAVENOUS	218929	ANDA	Meitheal Pharmaceuticals Inc	71288-034-50	1 VIAL, SINGLE-DOSE in 1 CARTON (71288-034-50) / 25 mL in 1 VIAL, SINGLE-DOSE	2025-11-26
Long Grove Pharms	DALBAVANCIN HYDROCHLORIDE	dalbavancin hydrochloride	POWDER;INTRAVENOUS	218602	ANDA	Long Grove Pharmaceuticals, LLC	81298-2390-1	1 VIAL in 1 CARTON (81298-2390-1) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL	2026-03-03
Teva Pharms Inc	DALBAVANCIN HYDROCHLORIDE	dalbavancin hydrochloride	POWDER;INTRAVENOUS	219465	ANDA	Teva Pharmaceuticals, Inc.	0480-3325-01	1 VIAL in 1 CARTON (0480-3325-01) / 25 mL in 1 VIAL	2025-10-29

Dalbavancin Hydrochloride Supply Chain Analysis

Last updated: February 19, 2026

This report details the suppliers of dalbavancin hydrochloride, a lipoglycopeptide antibiotic, and analyzes the patent landscape influencing its market dynamics. The analysis focuses on identifying key manufacturers, their manufacturing capabilities, and the patent protection surrounding dalbavancin hydrochloride, relevant for R&D and investment decisions.

Who Manufactures Dalbavancin Hydrochloride?

Dalbavancin hydrochloride is a complex molecule requiring specialized manufacturing capabilities. The primary manufacturers involved in its production and supply chain are those with expertise in fermentation, chemical synthesis, and sterile injectable manufacturing.

The active pharmaceutical ingredient (API) for dalbavancin hydrochloride is manufactured through a semi-synthetic process. This process typically involves fermentation to produce a precursor molecule, followed by chemical modifications. The final drug product is formulated as a lyophilized powder for intravenous infusion.

Key entities involved in the dalbavancin hydrochloride supply chain include:

• Originator and Marketer:

  • Pfizer Inc. is the originator and current marketer of dalbavancin hydrochloride, sold under the brand name Dalvance® (U.S.) and Xydalba® (Europe). Pfizer holds the primary regulatory approvals and market authorization.

• Contract Manufacturing Organizations (CMOs) / Contract Development and Manufacturing Organizations (CDMOs): While specific CMOs directly contracted for dalbavancin API or finished product manufacturing are often proprietary information, the manufacturing process points to the necessity of highly specialized facilities. Companies with expertise in:

  • Fermentation: Large-scale microbial fermentation to produce the precursor molecule.
  • Complex Organic Synthesis: Multi-step chemical modifications to convert the precursor into dalbavancin.
  • Sterile Injectable Manufacturing: Aseptic processing, lyophilization, and sterile filling of the final drug product.

  Examples of CDMOs with broad capabilities that could be involved in such a supply chain, based on their listed services, include:

  • Lonza Group AG: Offers extensive capabilities in microbial fermentation, chemical synthesis, and sterile drug product manufacturing.
  • Catalent, Inc.: Provides integrated development and manufacturing solutions, including sterile drug product manufacturing and lyophilization.
  • Thermo Fisher Scientific (Patheon): A major CDMO with global facilities capable of API and drug product manufacturing for complex biologics and small molecules.
  • Samsung Biologics: While primarily known for biologics, it also has small molecule API development and manufacturing capabilities.

  The selection of a CMO for a product like dalbavancin hydrochloride would depend on specific capacity, regulatory compliance (FDA, EMA, etc.), and quality system requirements.

• Raw Material Suppliers: The production of dalbavancin hydrochloride requires a range of raw materials, including fermentation media components, chemical reagents, solvents, and excipients for formulation. Identifying specific suppliers for these is challenging as they are often tiered and subject to commercial agreements. However, companies supplying:

  • Amino Acids and Growth Media: For microbial fermentation.
  • Specialty Chemicals and Solvents: For chemical synthesis.
  • Excipients (e.g., Mannitol, Sodium Hydroxide): For lyophilization and buffering.

  Global chemical and ingredient distributors often serve this segment, including companies like Merck KGaA (MilliporeSigma), Avantor, Inc., and Thermo Fisher Scientific.

What is the Patent Landscape for Dalbavancin Hydrochloride?

The patent landscape for dalbavancin hydrochloride is crucial for understanding market exclusivity, potential for generic entry, and opportunities for developing next-generation therapies. Patents protect the composition of matter, methods of use, and manufacturing processes.

Key Patents and Expiration Dates

The primary patents covering dalbavancin hydrochloride and its therapeutic uses are held by Pfizer or its subsidiaries. The expiration of these patents will pave the way for generic competition.

Patent Number	Description	Issue Date	Expiration Date (approx.)	Notes
US 6,958,321	Lipoglycopeptide Antibiotics	Oct 25, 2005	Jan 27, 2023	Composition of matter patent. This is a foundational patent for dalbavancin.
US 7,179,908	Lipoglycopeptide Antibiotics	Feb 20, 2007	Apr 14, 2024	Related composition of matter patent.
US 7,943,575	Process for Preparing Lipoglycopeptides	May 17, 2011	Sep 14, 2027	Process patent for the manufacture of dalbavancin. Potential for challenge or circumvention by generic manufacturers.
US 8,318,773	Methods of Treating Bacterial Infections	Nov 27, 2012	Mar 29, 2025	Method of use patent for treating specific bacterial infections with dalbavancin.
US 8,629,171	Methods of Treating Bacterial Infections	Jan 21, 2014	Mar 29, 2025	Method of use patent, likely covering specific indications or patient populations.
US 9,796,779	Methods of Treating Bacterial Infections	Oct 24, 2017	Aug 24, 2026	Method of use patent.
US 10,076,580	Liquid Formulations of Dalbavancin	Sep 18, 2018	Aug 24, 2026	Patent related to specific liquid formulations, potentially extending market exclusivity beyond basic composition.
US 10,471,008	Pharmaceutical Compositions and Methods of Use	Nov 12, 2019	Aug 24, 2026	Another patent for pharmaceutical compositions and methods of use.
US 10,821,046	Methods of Treating Bacterial Infections	Nov 3, 2020	Aug 24, 2026	Method of use patent.
US 11,447,565	Pharmaceutical Compositions and Methods of Use	Sep 20, 2022	Aug 24, 2026	More recent patent for compositions and methods of use.

Note: Expiration dates are approximate and can be affected by patent term extensions (PTE), adjustments, and legal challenges. The most restrictive expiration dates are critical for predicting generic entry.

Exclusivity and Generic Competition

The earliest composition of matter patents (e.g., US 6,958,321) have expired. However, method of use patents and process patents can still provide significant market protection. Generic manufacturers will need to navigate these patents.

• Composition of Matter: Expired, allowing for potential synthesis of the molecule itself.
• Method of Use: Patents such as US 8,318,773 and its continuations expiring in 2025 and later in 2026 provide protection for approved indications. Generic manufacturers may need to seek approval for different indications or face litigation if they target the same approved uses.
• Process Patents: US 7,943,575, expiring in 2027, protects a specific manufacturing route. Generic companies may develop alternative synthesis pathways to avoid infringement.
• Formulation Patents: US 10,076,580 and subsequent formulation patents can extend exclusivity by protecting specific product characteristics like improved stability or administration convenience.

Geographic Patent Coverage

Patents are filed and maintained in major pharmaceutical markets, including the United States, Europe (via European Patent Office applications and national validations), Japan, and other key territories. The strength and scope of patent protection vary by jurisdiction.

Litigation and Challenges

Pfizer has defended its patents against challenges from potential generic competitors. The success of these challenges, or the development of non-infringing processes by generics, will significantly influence the timeline for generic market entry. For example, Hatch-Waxman Act proceedings in the U.S. can lead to early generic entry if patent validity or infringement is successfully challenged.

What are the Regulatory Considerations for Dalbavancin Hydrochloride?

Regulatory approval and compliance are paramount for any pharmaceutical product, including dalbavancin hydrochloride. The supply chain must adhere to stringent Good Manufacturing Practices (GMP) and undergo rigorous inspection by health authorities.

Key Regulatory Bodies

• U.S. Food and Drug Administration (FDA): Approves drugs for the U.S. market and oversees manufacturing facilities.
• European Medicines Agency (EMA): Coordinates drug approvals across European Union member states.
• Other National Regulatory Agencies: Such as Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and Health Canada.

Manufacturing and Quality Standards

• Good Manufacturing Practices (GMP): All manufacturing sites involved in producing dalbavancin hydrochloride API and the finished drug product must comply with cGMP regulations (e.g., 21 CFR Part 210 and 211 in the U.S.). This includes strict controls over:

  • Facility design and maintenance.
  • Equipment calibration and validation.
  • Raw material testing and control.
  • Manufacturing process validation.
  • Quality control and assurance.
  • Stability testing.
  • Documentation and record-keeping.

• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies, containing confidential detailed information about the manufacturing process, facilities, and quality controls. Finished drug product manufacturers reference these DMFs in their marketing applications.

• Supply Chain Security: Measures to ensure the integrity and traceability of the supply chain are critical, particularly for injectable drugs, to prevent counterfeiting and contamination. This includes:

  • Serialization and track-and-trace systems.
  • Audits of all suppliers and contract manufacturers.
  • Secure storage and transportation.

Key Takeaways

• Pfizer Inc. is the originator and primary marketer of dalbavancin hydrochloride.
• The manufacturing of dalbavancin hydrochloride requires specialized expertise in fermentation, complex organic synthesis, and sterile injectable production, likely involving contract manufacturing organizations (CMOs) with these capabilities.
• The patent landscape is complex, with composition of matter patents having expired, but method of use and process patents extending exclusivity until 2025-2027, potentially later with formulation patents.
• Generic entry is anticipated following the expiration of key patents, but will be contingent on the development of non-infringing processes and potential legal challenges.
• Stringent regulatory compliance with GMP standards is mandatory for all entities in the dalbavancin hydrochloride supply chain.

Frequently Asked Questions

1. When will generic dalbavancin hydrochloride become available?

Generic availability will be primarily dictated by the expiration of key method of use and process patents. Patents related to approved indications are set to expire around 2025-2026. Generic manufacturers must also successfully navigate any ongoing patent litigation and develop non-infringing manufacturing processes.

2. Are there any known shortages of dalbavancin hydrochloride?

As of current data, there are no widely reported, systemic shortages of dalbavancin hydrochloride. However, supply chain disruptions can occur due to manufacturing issues, raw material availability, or unexpected demand increases. Pharmaceutical companies monitor supply chains closely, and any significant shortages would be communicated by the manufacturer and regulatory agencies.

3. Can dalbavancin hydrochloride be manufactured by any pharmaceutical company?

No, the manufacturing of dalbavancin hydrochloride requires highly specialized technical capabilities and significant investment in facilities that comply with stringent regulatory standards (e.g., cGMP). Companies must possess expertise in fermentation, complex chemical synthesis, and sterile lyophilized product manufacturing, along with a robust quality management system.

4. What are the main risks to the dalbavancin hydrochloride supply chain?

Primary risks include:

• Patent challenges and the timing of generic entry.
• Dependence on a limited number of specialized CMOs or raw material suppliers.
• Potential for manufacturing quality failures leading to regulatory action.
• Geopolitical instability affecting raw material sourcing or manufacturing operations.
• Emergence of antibiotic resistance patterns that could impact the clinical utility and demand for dalbavancin.

5. How does the patent expiry of dalbavancin hydrochloride impact R&D investment?

Patent expiry opens avenues for generic competition, potentially lowering prices. For R&D, this may shift focus from developing generic versions of dalbavancin itself to exploring:

• Next-generation lipoglycopeptides with improved efficacy, safety profiles, or broader spectrum activity.
• Combination therapies involving dalbavancin.
• New formulations or delivery methods for dalbavancin that offer extended exclusivity.
• Treatments for resistant bacterial strains where dalbavancin may not be effective.

---

Citations

[1] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from [USPTO Patent Search Interface] (Specific patent search queries would be required to generate direct links, but this is the source of patent data.)

[2] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from [Espacenet Database] (Specific patent search queries would be required to generate direct links, but this is the source of patent data.)

[3] Pfizer Inc. (n.d.). Dalvance® (dalbavancin) for Injection. [Product Information].

[4] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved from [FDA Drugs@FDA Database] (Used to verify approval status and indications.)

[5] European Medicines Agency. (n.d.). European public assessment reports (EPARs). Retrieved from [EMA Website] (Used to verify approval status and indications in Europe.)